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Abstract
Homocystinuria is an inherited metabolic disease biochemically characterized by tissue accumulation of homocysteine (Hcy). Mental
retardation, ischemia and other neurological features, whose mechanisms are still obscure are common symptoms in homocystinuric
patients. In this work, we investigated the effect of Hcy administration in Wistar rats on some parameters of energy metabolism in the
hippocampus, a cerebral structure directly involved with cognition. The parameters utilized were 14CO2 production, glucose uptake,
lactate release and the activities of succinate dehydrogenase and cytochrome c oxidase (COX). Chronic hyperhomocysteinemia was
induced by subcutaneous administration of Hcy twice a day from the 6th to the 28th day of life in doses previously determined in our
laboratory. Control rats received saline in the same volumes. Rats were killed 12 h after the last injection. Results showed that Hcy
administration significantly diminished 14CO2 production and glucose uptake, as well as succinate dehydrogenase and COX activities.
It is suggested that impairment of brain energy metabolism may be related to the neurological symptoms present in homocystinuric
patients.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Hyperhomocysteinemia is the biochemical hallmark of
homocystinuria (HCU), an inborn error of metabolism
caused by severe deficiency of cystathionine h-synthase
(CBS, EC 4.2.1.22) activity. Affected patients usually
present a variable degree of neurological dysfunction, ocular
and vascular complications [1,2]. Although the thromboem-
bolic features of HCU are thought to be due to vascular
lesions induced by homocysteine (Hcy), the mechanisms
underlying the variable degree of mental retardation occur-
ring in the affected patients are not yet established.
There is a considerable body of evidence showing that
increased plasma Hcy level is a strong and independent risk
factor for the development of some neurodegenerative dis-
eases such as dementia, Alzheimer’s disease and Parkinson’s
disease [3–7], in which cellular energy depletion was found
to be associated [8–12]. Furthermore, mitochondrial abnor-
malities that reflect compromised energy metabolism have
been identified in hepatocytes of patients with hyperhomo-
cysteinemia and in endothelial cells from the aorta of hyper-
tensive rats with diet-induced hyperhomocysteinemia
[13,14].
Animal models are useful to better understand the
pathophysiology of diseases. We have recently developed
in our laboratory a chemical experimental model of hyper-
homocysteinemia [15], in which the Hcy levels were
similar to those found in human HCU [1]. In the present
study, we used this model to investigate the effect of high
sustained Hcy levels on some parameters of energy metab-
olism, namely 14CO2 production, glucose uptake and the
activities of succinate dehydrogenase and cytochrome c
oxidase (COX) in rat hippocampus, in the hope of better
understanding the mechanisms underlying the neurological
dysfunction found in homocystinuric patients.
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2. Materials and methods
2.1. Reagents
All chemicals were purchased from Sigma Chemical Co.,
St. Louis, MO, USA, except for the radiolabeled compound
[U-14C] acetate which was purchased from Amersham
International PLC, UK.
2.2. Animals
Wistar rats obtained from the Central Animal House of
the Departamento de Bioquı´mica, ICBS, UFRGS were
used. Rats were kept with dams while receiving the drugs
until weaning at 21 days of age. The animals had free
access to water and to a standard commercial chow and
were maintained on a 12:12 h light/dark cycle in an air-
conditioned constant temperature (22F 1 jC) colony
room. The ‘‘Principles of Laboratory Animal Care’’
(NIH publication 85-23, revised 1985) were followed in
all the experiments and the experimental protocol was
approved by the Ethics Committee for Animal Research
of the Federal University of Rio Grande do Sul, Poˆrto
Alegre.
2.3. Chemically-induced hyperhomocysteinemia
Hcy was dissolved in 0.9% NaCl solution and buffered
to pH 7.4. Hcy solution was administered subcutaneously
twice a day at 8-h intervals from 6 to 28 days of age.
Control animals received saline solution in the same
volumes as those applied to Hcy-treated rats. Hcy doses
were calculated from pharmacokinetic parameters previ-
ously determined in our laboratory [15]. During the first
week of treatment, animals received 0.3 Amol Hcy/g body
weight. In the second week, 0.4 Amol Hcy/g body weight
was administered to the animals, and in the last week rats
received 0.6 Amol Hcy/g body weight. Rats subjected
to this treatment achieved plasma Hcy levels similar to
those found in homocystinuric patients. Treated animals
achieved maximal plasma Hcy levels 15 min after sub-
cutaneous injection of Hcy (0.40–0.50 mmol/l). Maximal
brain levels were achieved 15 min after Hcy administration
(0.04–0.06 mmol/kg wet weight tissue). Twelve hours
after treatment, plasma Hcy concentrations returned to
normal levels (0.01 mmol/l) and brain Hcy levels were
not detected.
2.4. Tissue and homogenate preparation
Twelve hours after the last injection, animals were
sacrificed by decapitation, the brain was rapidly removed
and the hippocampus was isolated. Hippocampus was cut
into two perpendicular directions to produce 400-Am-wide
prisms using a McIlwain chopper. Prisms were pooled,
weighed and used for 14CO2 production, lactate release
and glucose uptake assays. For succinate dehydrogenase
and COX activities determination, hippocampus was
homogenized (1:10, w/v) in SETH buffer, pH 7.4 (250
mM sucrose, 2 mM EDTA, 10 mM Trizma base, 50 UI
ml 1 heparin). The homogenates were centrifuged at
800 g for 10 min and the supernatants kept at  70
jC until used for enzyme activity determination. The
maximal period between homogenate preparation and
enzyme analysis was always less than 5 days.
2.5. 14CO2 production
Hippocampus prisms (50 mg) were added to small
flasks (11 cm3) containing 0.5 ml Krebs–Ringer bicarbon-
ate buffer, pH 7.4, 0.2 ACi [U-14C] acetate and 0.5 mM of
the unlabeled acetate. The flasks were gassed with a O2/
CO2 (95:5) mixture and sealed with rubber stoppers and
Parafilm M. Glass center wells containing a folded 65 mm/
5 mm piece of Whatman 3 filter paper were hung from the
stoppers. After 60 min of incubation at 37 jC in a
metabolic shaker (90 oscillationsmin 1), 0.1 ml of
50% trichloroacetic acid was added to the medium and
0.1 ml of benzethonium hydroxide was added to the center
of the wells with needles introduced through the rubber
stopper. The flasks were left to stand for 30 min to
complete 14CO2 trapping. The filter papers were removed
and added to vials containing scintillation fluid, and radio-
activity was counted [16].
2.6. Lactate release
Hippocampus prisms (50 mg) were incubated under an
O2/CO2 (19:1) mixture at 37 jC for 60 min in Krebs–
Ringer bicarbonate buffer, pH 7.0 (in a total volume of 1
ml) in a metabolic shaker (90 oscillationsmin 1) [17].
Two volumes of 0.6 N perchloric acid were immediately
added to the prisms and the excess of perchloric acid was
precipitated as a potassium salt by the addition of one
volume of a solution containing 0.5 N KOH, 0.1 M
imidazol, and 0.1 KCl. The solution was then centrifuged
for 5 min at 800 g. Lactate was measured in the medium
before and after incubation by the lactase–peroxidase
method [18]. Lactate release was calculated by subtracting
lactate content found after incubation from the amount
found before incubation. Lactate concentrations in the
medium at the beginning of the incubation were practically
nilled.
2.7. Glucose uptake
Hippocampus prisms (100 mg) were incubated in
Krebs–Ringer bicarbonate buffer, pH 7.0 (in a total
volume of 1 ml), containing 5.0 mM glucose in a O2/
CO2 (19:1) mixture in a metabolic shaker (90 oscil-
lationsmin 1) at 37 jC for 60 min [17]. Glucose was
measured by the glucose oxidase method [19] and the
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uptake determined by subtracting the amount after incuba-
tion from the total amount measured before incubation.
2.8. Respiratory chain enzyme activities
2.8.1. Succinate dehydrogenase activity
The activity of succinate: phenazine oxireductase (solu-
ble SDH) was measured in hippocampus homogenates
following the decrease in absorbance due to the reduction
of 2,6-dichloroindophenol (DCIP) at 600 nm with 700 nm
as reference wavelength (e = 19.1 mM 1 cm 1) in the
presence of phenazine methasulfate (PMS), according to
Fischer et al. [20]. The reaction mixture consisting of 40
mM potassium phosphate, pH 7.4, 16 mM succinate and 8
AM DCIP was preincubated with 40–80 Ag homogenate
protein at 30 jC for 20 min. Subsequently, 4 mM sodium
azide, 7 AM rotenone and 40 AM DCIP were added and the
reaction was initiated by addition of 1 mM PMS and was
monitored for 5 min.
2.8.2. Cytochrome c oxidase activity
COX activity was determined according to Rustin et al.
[21]. Enzymatic activity was measured at 25 jC for 10
min by following the decrease in absorbance due to
oxidation of previously reduced cytochrome c at 550 nm
with 580 nm as reference wavelength (e = 19.1 mM 1
cm 1). The reaction buffer contained 10 mM potassium
phosphate, pH 7.0, 0.6 mM n-dodecyl-h-D-maltoside, 2–4
Ag homogenate protein and the reaction was initiated by
addition of 0.7 Ag reduced cytochrome c. Reaction time
and protein concentration were chosen to ensure the
linearity of the reaction.
2.9. Protein determination
Protein was measured by the method of Lowry et al. [22]
using bovine serum albumin as standard.
2.10. Statistical analysis
Data were analyzed by Student’s t-test. All analyses were
performed using the Statistical Package for the Social
Sciences (SPSS) software.
Fig. 1. Effect of chronic administration of homocysteine on 14CO2
production (A), lactate release (B) and glucose utilization (C) in rat
hippocampus. Data are expressed as meanF S.D. for four to five
independent experiments (animals) performed in duplicate. Different from
control, **P < 0.01 (Student’s t-test).
Fig. 2. Effect of chronic administration of homocysteine on succinate
dehydrogenase (A) and cytochrome c oxidase (B) activities in rat
hippocampus. Data are expressed as meanF S.D. for five independent
experiments (animals) performed in duplicate. Different from control,
*P < 0.05, **P < 0.01 (Student’s t-test). SDH—succinate dehydrogenase;
COX—cytochrome c oxidase.
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3. Results
Fig. 1 shows that Hcy administration significantly
inhibited 14CO2production [t(8) = 3.82;P < 0.01] and glucose
uptake [t(6) = 3.67; P < 0.01] in rat hippocampus, when com-
pared to the control group (saline). In contrast, lactate release
was not affected by this treatment [t(8) = 0.69; P>0.05].
We also examined the effect of hyperhomocysteinemia
on the brain respiratory chain enzyme activities by measur-
ing succinate dehydrogenase and COX activities in the rat
hippocampus. As can be observed in Fig. 2, Hcy admin-
istration significantly inhibited succinate dehydrogenase
[t(8) = 2.93; P < 0.01] and COX [t(8) = 2.63; P < 0.05] activ-
ities in this cerebral structure.
4. Discussion
HCU is an inborn error of metabolism caused by severe
deficiency of CBS activity. Affected patients present tissue
accumulation of Hcy, and clinically, mental retardation,
brain ischemia, seizures and other neurological features.
However, the mechanisms underlying the neurological dys-
function of HCU are still poorly known [1]. The under-
standing of the biochemical alterations in brain might
possibly contribute to a better therapeutic management of
homocystinuric patients.
The purpose of the present investigation was to evaluate
some biochemical parameters of brain energy metabolism,
namely 14CO2 production, glucose uptake, lactate release,
succinate dehydrogenase and COX activities in the hippo-
campus of rats subjected to chronic chemically-induced
hyperhomocysteinemia. We produced high plasma sustained
levels of Hcy in rats (up to 50-fold higher than in controls)
similar to those found in homocystinuric patients [1]. Brain
levels were also significantly increased [15].
First, we investigated the effect of hyperhomocysteinemia
on the activity of the Krebs cycle by measuring 14CO2
production from acetate. The anaerobic metabolism was
evaluated by lactate release. We verified that Hcy adminis-
tration significantly reduced 14CO2 production and glucose
uptake, but did not alter lactate production. Taken together,
these findings suggest that chronic Hcy administration prob-
ably reduce aerobic glycolysis and glucose uptake. It is
feasible that lactate production was not altered probably
because brain glucose utilization was decreased. It can there-
fore be presumed that the reduction of Krebs cycle activity
caused by Hcy administration might lead to a reduced energy
production.
The next experiments were performed in order to eval-
uate the respiratory chain function by measuring succinate
dehydrogenase and COX activities in the hippocampus of
rats subjected to chronic administration of Hcy. We verified
that Hcy markedly inhibited both activities. Therefore, it is
possible that the reduction of these enzyme activities, which
are considered markers of neuronal function, by Hcy admin-
istration might explain the reduction of glucose uptake and
14CO2 production (Krebs cycle) observed. However, we
cannot establish at the present whether the degree of
inhibition of the electron transfer chain caused by Hcy
would alter ATP biosynthesis, and this is presently being
carried out in our laboratory.
COX is the terminal and rate-limiting enzyme of the
mitochondrial respiratory chain, catalyzing the transfer of
electrons from cytochrome c to molecular oxygen [23].
Therefore, an inhibition of this enzyme can potentially lead
to incomplete reduction of oxygen, and consequently to
increased free radical formation and reduced ATP synthesis
[24–26]. On the other hand, since oxidative phosphorylation
is very active in the brain [27,28], it is postulated that
inhibition of the respiratory chain at two crucial complexes
caused by high sustained levels of Hcy may be highly
damaging to this tissue. Furthermore, considering previous
findings from our and other laboratories demonstrating that
Hcy impairs memory in rats [29], inhibits Na+,K+-ATPase in
rat hippocampus [15,30–32], and induces neuronal death in
culture of cerebellar granule cells [33], it is possible that the
deficit of energy metabolism may underlie, at least partially,
some of these observations, representing therefore an impor-
tant mechanism responsible for the neurological damage in
HCU.
On the other hand, it has been shown that reduction of
brain energy production might compromise neurotransmitter
(acetylcholine, glutamate, aspartate and GABA) and lipid
synthesis, which might lead to neurological damage [34].
Lack of energy production may also cause a deficient
glutamate uptake by glial cells and by neurons and even a
reversion of the transporters, leaving excess of glutamate in
the synaptic cleft and causing secondary excitotoxicity
[5,35–40]. This is interesting in view of previous studies
reporting that Hcy induces neuronal death mediated by
activation of NMDA receptors [33]. These investigators
also observed that Hcy enhanced free radical generation,
which may in turn induce mitochondrial damage [41]. In
this context, it is well known that mitochondria generate
various reactive oxygen species, such as superoxide anions,
hydroxyl radicals and hydrogen peroxide [42].
It is difficult to predict whether we can extrapolate our
findings to the human condition. However, if the inhibition
of energy metabolism caused by chronic Hcy treatment also
occurs in humans, it may be presumed that impaired energy
metabolism is associated with the neurological symptoms
present in homocystinuric patients. Whether this or other
abnormalities, such as oxidative stress or excitotoxicity, is
mainly responsible for brain damage in homocystinuric
patients is a matter for further investigation.
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